BMI View: Medicine shortages and a lack of funding are two of the greatest challenges facing Sudan and
South Sudan's pharmaceutical and healthcare markets. The Sudanese government will step up its efforts to
reduce these recurring issues through improvements to the do ..."
BMI View: Over the coming years, the Sudanese government will look to address the recurring issues of
medicine shortages and a lack of funding through improvements to the domestic pharmaceutical industry.
In turn, this will reduce its reliance on imported medicines; h ..."
BMI View: Sudan is attempting to reduce its reliance on imported pharmaceuticals with government
support. Despite an investment from an Egyptian drugmaker this quarter, the country will not achieve this
goal in the near future given the current political environment. ..."
BMI View: Due to the lack of production capacity among domestic companies, the majority of
pharmaceuticals in Sudan and South Sudan will remain sourced from abroad. Over the long-term, domestic
manufacturers will increase their market share, with the government placin ..."
BMI View: Access to healthcare in Sudan and South Sudan is poor and drug shortages are commonplace.
The state is also heavily reliant on importing its medicines, though over the long-term we believe this
reliance will decrease as the government is committed to develop ..."
BMI View: The already depreciating Sudanese pound will come under further strain should oil prices
continue their decline as oil exports account for around 70% of total exports in the country. We are already
forecasting short-term negative growth in US dollar terms for the phar ..."
BMI View: Overall pharmaceutical sales in Sudan and South Sudan are to see double-digit growth, albeit
from a low base. In addition, we highlight that high inflation, volatile currency exchange rates and civil
unrests are some of the key risks that will continue to li ..."
BMI View: Despite an improvement in Sudan's Pharmaceutical Risk/Reward Ratings, we note that risks in
the country far outweigh any possible rewards for pharmaceutical firms. This is due to a variety of reasons,
some of which are industry-specific (eg, Sudan's failure ..."
BMI View: Disparity in the official and black market currency exchange rates, corruption and continual
political tensions between Sudan and South Sudan will remain as downside risks to investments into the
pharmaceutical sector. Consequently, we do not expect the mark ..."
BMI View: Sudan will remain one of the least attractive countries in the Middle East/Africa region due to low pharmaceutical and healthcare expenditure. The government's low commitment to healthcare, combined with political and economic uncertainties, will remain a downside risk ..."